216 related articles for article (PubMed ID: 35203668)
1. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.
Gil J; Marques-Pamies M; Valassi E; García-Martínez A; Serra G; Hostalot C; Fajardo-Montañana C; Carrato C; Bernabeu I; Marazuela M; Rodríguez-Lloveras H; Cámara R; Salinas I; Lamas C; Biagetti B; Simó-Servat A; Webb SM; Picó A; Jordà M; Puig-Domingo M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203668
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.
Gil J; Jordà M; Soldevila B; Puig-Domingo M
Front Endocrinol (Lausanne); 2021; 12():646210. PubMed ID: 33790868
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas.
Gil J; Marques-Pamies M; Jordà M; Fajardo-Montañana C; García-Martínez A; Sampedro M; Serra G; Salinas I; Blanco A; Valassi E; Sesmilo G; Carrato C; Cámara R; Lamas C; Casano-Sancho P; Alvarez CV; Bernabéu I; Webb SM; Picó A; Marazuela M; Puig-Domingo M;
Clin Endocrinol (Oxf); 2021 May; 94(5):811-819. PubMed ID: 32978826
[TBL] [Abstract][Full Text] [Related]
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?
Fleseriu M; Hoffman AR; Katznelson L;
Endocr Pract; 2015 Jun; 21(6):668-73. PubMed ID: 26135961
[TBL] [Abstract][Full Text] [Related]
5. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
8. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
9. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Henriques DG; Miranda RL; Dezonne RS; Wildemberg LE; Camacho AHDS; Chimelli L; Kasuki L; Lamback EB; Guterres A; Gadelha MR
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769196
[TBL] [Abstract][Full Text] [Related]
10. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
van der Lely AJ; Kuhn E; Muhammad A; Coopmans EC; Neggers SJ; Chanson P
Eur J Endocrinol; 2020 Jun; 182(6):D17-D29. PubMed ID: 32234975
[TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).
Brunetti A; Antonini S; Saladino A; Lavezzi E; Zampetti B; Cozzi R
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744057
[TBL] [Abstract][Full Text] [Related]
12. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
13. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
14. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.
Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092
[TBL] [Abstract][Full Text] [Related]
16. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
17. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
18. The role of combination medical therapy in the treatment of acromegaly.
Lim DS; Fleseriu M
Pituitary; 2017 Feb; 20(1):136-148. PubMed ID: 27522663
[TBL] [Abstract][Full Text] [Related]
19. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.
Lekva T; Berg JP; Heck A; Lyngvi Fougner S; Olstad OK; Ringstad G; Bollerslev J; Ueland T
PLoS One; 2013; 8(6):e66927. PubMed ID: 23825587
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
